2018 was a year in line with expectations
- 2018 revenue of DKK 10,410 million
- Strong progress on 2025 Strategy
- Strengthened innovative clinical pipeline
- Expanded established portfolio
LEO Pharma’s consolidated revenue amounted to DKK 10,410 million in 2018, a level similar to revenue in 2017 (DKK 10,481 million).
Operating profit increased from DKK 852 million in 2017 to DKK 1,605 million in 2018. The increase in operating profit was predominantly driven by the strategic decision to divest LEO Pharma’s non-strategic derma portfolio to Karo Pharma AB. The divestment resulted in a net gain of DKK 1,566 million recognized as other operating income.
Find our Annual Reports and Annual Results press releases listed in the side column.